[1] Goodman MT, McDuffie K, Hemandez BY, et al. The influence of multiple human papilloma virus stypes on the risk of genotype-concordant incident infections of theanus andcervix: the Hawaii HPV cohort study. J Infect Dis. 2011;203(3): 335-340.[2] Sukasem C, Pairoj W, Saekang N, et al. Molecular epidemiology of human papillomavirus genotype in women with high-grade squamous intraepithelial lesion and cervical cancer:will a quadrivalent vaccine be necessary in Thailand? J Med Viro. 2011;83(1):119-126.[3] Zhang D, Zhang Q, Zhou L, et al. Comparison of prevalence, viral load, physical status and expression ofhuman papillomavirus-16, -18 and -58 in esophageal and cervica lcancer: a case-controls tudy. BMC Cancer. 2010;10:650.[4] Nicolás-Párraga S, Gandini C, Pimenoff VN, et al. HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus. Cancer Med. 2016;5(10):2909- 2919.[5] Li H, Anuwongcharoen N, Malik AA, et al. Roles of d-Amino Acids on the Bioactivity of Host Defense Peptides. Int J Mol Sci. 2016;17(7):34-36.[6] Liang YK, Zeng, Xiao YS, et al. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERá expression and AKT activation. Cancer Lett. 2016.[7] Garcia-Montoya IA, Cendon TS, Arevalo-Gallegos S, et al. Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta. 2012;1820(3):226-236.[8] Luo G, Zhou Y, Yi W, et al. Lactotransferrin expression is downregulated and affects the mitogen-activated protein kinase pathway in gastric cancer. Oncol Lett. 2015;9(5): 2409-2413.[9] Mariller C, Hardivill S, Hoedt E, et al. Proteomic approach to the identification of novel delta-lactoferrin target genes: characterization of DcpS,an mRNA scavenger decapping enzyme. Biochimie. 2009;91(1):109-122. [10] Morad SA, Cabot MC. Tamoxifen regulation of sphingolipid metabolism-Therapeutic implications. Biochim Biophys Acta. 2015;1851(9):1134-1145.[11] Li H, Anuwongcharoen N, Malik AA,et al. Roles of d-amino acids on the bioactivity of host defense peptides. Int J Mol Sci. 2016;17(7):E1023.[12] Yamada Y, Sato R, Kobayashi S, et al. The antiproliferative effect of bovine lactoferrin on canine mammary gland tumor cells. J Vet Med Sci. 2008;70(5):443-448.[13] Suda H, Sekine K, Takasuka N, et al. Prevention of colon carcinogenesis and carcinoma metastasis by orally administered bovine lactoferrin in animals. Biofactors. 2000; 12(1-4):83-88.[14] Iigo M, Kuhara T, UshidaY et al. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin Exp Metastasis. 1999;17(1):35-40.[15] Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74-79.[16] Shi H, Li W. Inhibitory effects of human lactoferrin on U14 cervical carcinoma through upregulation of the immune response. Oncol Lett. 2014;7(3):820-826.[17] Vorland LH. Lactoferrin: a multifunctional glycoprotein. APMIS. 1999;107:971.[18] van der Strate BWA, Beljaars L, Molema G, et al. Antiviral activities of lactoferrin. Antivir Res. 2001;52:225-228.[19] 刘自明,严律南.细菌内同源重组法制备腺病毒介导 TK 基因对肝癌细胞的杀伤作用[J].四川大学学报,2007,38(2):205-208. [20] Chen GX, Zhang S, He XH, et al. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther. 2014;7:1901-1909. [21] Putzer BM, Bramson JL, Addison CL, et al. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectoes potentiates tumor regression in amuring model of breast cancer. Hum Gene Ther. 1998;9(5):707-718. [22] 韩德民,黄志刚,张伟,等.重组人 p53 腺病毒注射液治疗喉癌的Ⅰ期临床实验及追踪观察[J].中华医学杂志,2003,83(23): 2029-2032. [23] Bai J, Li J, Mao Q, et al. Construction of a single lentiviral vector containing tetracycline-inducible Alb-uPA for transduction of uPA expression in murine hepatocytes. PLoS One. 20133;8(4):e61412. [24] 李萍,王德华.ABCE1基因沉默对人宫颈癌XB1702细胞生物学特性的影响[J].中国组织工程研究,2015,19(37):5972-5977.[25] Yu Z, Jiang Q, Liu J, et al. A simplified system for generating recombinant E3-deleted canine adenovirus-2. Plasmid. 2015; 77:1-6. [26] Ng P, Parks RJ, Cummaings DT, et al. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther. 2000;11(5):693-699. [27] Hong JS, Engler JA. Domains required for assembly of adenovirus type 2 fiber trimers. J Virol. 1996;70:7071-7078. [28] 韩玉刚,李建凡.动物生物反应器的研究现状和进展[J].国外畜牧科技,2002,29(1):30-33. [29] McEcoy TG, Sreenan J M. The efficiency of production, centrifugation and transfer of one and two-cell bovine ova in a gene transfer program. Theriogenology. 1990;33:819-828. [30] Halter R. Strategies to express factor Ⅷ gene constructs in the ovine mammary gland. Theriogenologr. 1993;39:137-149.[31] Roy K, Patel YS, Kanwar RK, et al. Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells. Int J Nanomedicine. 2015;11:25-44. [32] Sohrabi SM, Niazi A, Chahardoli M, et al. In silico investigation of lactoferrin protein characterizations for the prediction of anti-microbial properties. Mol Biol Res Commun. 2014;3(2):85-100.[33] Jones EM, Smart A, Bloomberg G, et al. Lactoferricin a new antimicrobial peptide. Appl Bacteriol. 1994;77(2):208-214. [34] Barber MF, Kronenberg Z, Yandell M, et al. Antimicrobial functions of lactoferrin promote genetic conflicts in ancient primates and modern humans. PLoS Genet. 2016;12(5): e1006063. [35] Zhang H, Feng X, Liu W, et al. Underling mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. J Cell Biochem. 2011;112(7):1832-1843.[36] Li WY, Li QW, Han ZS, et al. Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm. 2011;26(4):477-483.[37] Fujita K, Matsuda E, Sekine K, et al. Lactoferrin modifies apoptosis-related gene expression in the colon of the azoxymethane-treated rat. Cancer Lett. 2004;213(1):21-29.[38] Sakai T, Banno Y, Kato Y, et al. Pepsin-digestedbovine lactofemninduces cell death with JNK/SAPK activation in oral cancer cells. Japoptotic Pharmacol Sci. 2005;98(1):41-48.[39] Wang J, Li Q, Ou Y, et al. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tunlor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res. 2011;34(6):987-995. [40] Lee SH, Park SW, Pyo CW, et al. Requirement of the JNK-associated Bcl.2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. Biochimie. 2009; 91(1):102-108. |